Use of Janus kinase inhibitors in dermatomyositis: a systematic literature review
Authors' conclusion
Although the conclusions that can be drawn from this analysis are limited because of the differences in assessments used across publications, overall treatment of patients with DM or JDM with a JAK inhibitor was associated with significant improvement of a wide range of DM manifestations, including skin lesions, muscle weakness, and ILD.
Study context
- Population
- Patients with dermatomyositis (DM) or juvenile DM (JDM) treated with a JAKi, reported in peer-reviewed publications (PubMed, Embase, Web of Science, Scopus, Dimensions)48 publications
- Participants
- 145 patients
- Comparison
- Adult DM vs JDM
- Adult DMn = 84
- JDMn = 61
- Outcome
- Improvement in refractory skin disease after JAKi
Methodological detailscase-level data from published reports, Assessments differed across publications
- Case-level data from published reports
- Assessments differed across publications
Main finding
As reported in the abstract
| Group | Value | Improved / with refractory skin disease |
|---|---|---|
| Adult DM | 61 events | 61 of 61 |
| JDM | 95% | 57 of 60 |
Value
Adult DM61 events
JDM95%
Improved / with refractory skin disease
Adult DM61 of 61
JDM57 of 60
Further findings
| Outcome | Adult DM | JDM |
|---|---|---|
| Improvement in refractory muscle disease | 16 events | 83% |
| Improved / with refractory muscle disease | 16 of 16 | 30 of 36 |
| Improvement in ILD | 94% | 4 events |
| With ILD | 33 | — not stated in the abstract |
| Reduction in serum IFN or IFN gene expression in those elevated at baseline | 17 events | 16 events |
— not stated in the abstract
Reduction in serum interferon (IFN) or IFN gene expression in those elevated at baseline
- All patients with elevated baseline IFN showed reduction
Original publication
Use of Janus kinase inhibitors in dermatomyositis: a systematic literature review. Clin Exp Rheumatol. Published 17 February 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →